PubMed Health⌕ Search

Biomedical subjects

C H McIntosh

Publications and source records attributed to C H McIntosh.

At least 73 records · Page 4Linked to original sources
PubMed1985

Gastrointestinal somatostatin: distribution, secretion and physiological significance.

Somatostatin-like immunoreactivity (SLI) has been found throughout the gastrointestinal tract in all species examined. In the stomach it is mainly present in endocrine-type D-cells whereas in the intestine there is also an extensive distribution in enteric neurones. In all regions of the gastrointestinal tract multiple forms of somatostatin exist. A precursor (prosomatostatin) has been partially sequenced, three forms with 20 (SS-20), 25 (SS-25) and 28 (SS-28) amino acids completely sequenced, and somatostatin-14 (SS-14) demonstrated by radioimmunoassay. Both SS-14 and SS-28 exert a wide range of actions on the gastrointestinal tract and there is strong supportive evidence for a role in the regulation of gastric acid and gastrin secretion, gastrointestinal motility and intestinal transport. Both in vivo and in vitro studies on the secretion of gastric SLI into the vasculature have shown that nutrients initiate the process but that subsequent events are regulated by a complex interplay between hormonal and neuronal pathways. GIP is one of the most potent hormonal secretagogues. In the stomach, acetylcholine, opioid peptides and substance P are probably involved in parasympathetic inhibitory pathways and gastrin releasing peptide in stimulatory pathways. The sympathetic nerves are also stimulatory. Regulation of secretion of intestinal SLI has not been so extensively studied. Although SLI is also found in the gastrointestinal lumen the significance is unclear. Despite these advances the exact route of delivery of somatostatin to its target organs is uncertain and paracrine, endocrine and neural pathways may all be involved.

Animals↗
PubMed1985

Central somatostatin systems revealed with monoclonal antibodies.

The distribution of central neurons displaying somatostatin immunoreactivity was studied using three monoclonal antibodies to cyclic somatostatin. The sensitive ABC immunoperoxidase technique was employed. A large number of positive cell groups including many previously undescribed populations were detected throughout the brain and spinal cord. Telencephalic somatostatin neurons included periglomerular cells in the olfactory bulb, mitral cells in the accessory olfactory bulb, and multipolar cells in the anterior olfactory nuclei, neocortex, amygdala, hippocampus, lateral septum, striatum, and nucleus accumbens. Within the hypothalamus, positive neurons were found in the periventricular, suprachiasmatic, and arcuate nuclei, and throughout the anterior and lateral hypothalamus. The entopeduncular nucleus and zona incerta contained many positive neurons, and the lateral habenula had a dense terminal field suggesting a pallidohabenula somatostatin pathway. Somatostatin neurons were also found in association with many sensory systems. Positive cells were present in the superior and inferior colliculi, the ventral cochlear nuclei, the ventral nucleus of the lateral lemniscus, nucleus cuneatus, nucleus gracilus, and the substantia gelatinosa. Various cerebellar circuits also displayed somatostatin immunoreactivity. Golgi cells throughout the cerebellar cortex were intensely stained, and some Purkinje cells in the paraflocculus also showed a positive reaction. Positive fibers were present in the granular layer and large varicose fibers were present in the inferior cerebellar peduncle. Many nuclei known to project to the cerebellum, including the nucleus reticularis tegmenti pontis, the medial accessory inferior olive, the nucleus prepositus hypoglossi, and many areas of the reticular formation contained positive neurons. These studies demonstrate that these new monoclonal antibodies are of great value for the study of central somatostatin systems. Previously described somatostatin systems are readily detected with these antibodies, and in addition, many otherwise unrecognized somatostatin cell groups have been discovered.

Animals↗
PubMed1985

An immunocytochemical investigation with monoclonal antibodies to somatostatin.

Four monoclonal antibodies specific for somatostatin have been produced and characterized. These antibodies were used to assess the anatomical relationship of somatostatin-containing cells in the pancreas and gastrointestinal tract of man, baboon and rat with ten other peptide-containing endocrine cells. The peptides investigated were gastrin, cholecystokinin, motilin, secretin, neurotensin, gastric inhibitory polypeptide, gut-glucagon, pancreatic glucagon, pancreatic polypeptide and insulin. The only regions in which somatostatin cells were seen in close contact with another endocrine cell were in the pancreas and the gastric antrum. In the pancreas somatostatin cells were commonly seen in close contact with insulin, glucagon and pancreatic polypeptide cells and infrequent contact was demonstrable with the gastrin-immunoreactive cells in the antrum of both rat and man. In all other cases no evidence was obtained for a close anatomical relationship between somatostatin cells and the other enteroendocrine cells.

Animals↗
PubMed1985

Effect of substance P on somatostatin release from the isolated perfused rat stomach.

The effect of substance P (SP) on the release of gastric somatostatinlike immunoreactivity (SLI) was studied. Substance P inhibited both basal SLI release and SLI release stimulated by gastric inhibitory polypeptide or 1-isoproterenol. This inhibitory action of SP was not blocked by atropine or hexamethonium, suggesting that a cholinergic mechanism was not involved. The SP-suppressed SLI release was also not reversed by the administration of naloxone, which indicated that enkephalinergic involvement was absent. However, the SP antagonist [D-Pro2, D-Trp7,9]-SP abolished the inhibition of SLI release by SP. It is concluded that SP might be involved in the control of gastric SLI release and that the inhibitory action of SP was probably mediated directly or indirectly on the gastric D cells through SP receptors.

Animals↗
PubMed1985

Autoradiographic localization of binding sites for atrial natriuretic factor.

The distribution of atrial natriuretic factor (ANF) binding sites in Wistar rat tissues, as well as tissues from other species was studied. Using autoradiography of slide mounted tissue sections incubated with 125I-labelled ANF, high densities of binding sites were found in the renal glomeruli and papilla, aortic smooth muscle, iliac vein, choroid plexus, anterior pituitary, lung, and adrenal zona glomerulosa. Results from renal, aortic, adrenal, and lung tissues from spontaneously hypertensive rats did not differ from those of Wistar rats. Binding sites were also observed in guinea pig glomeruli, renal medulla, and aorta as well as in the rabbit aorta.

Adrenal Cortex↗
PubMed1985

The effect of met-enkephalin and naloxone on somatostatin and insulin secretion from the isolated, perfused rat pancreas.

The effect of met-enkephalin and the opiate antagonist, naloxone, on somatostatin and insulin secretion from the isolated, perfused rat pancreas has been studied during perfusion with 300 mg/dl glucose. In response to a gradient of met-enkephalin from 0 to 10(-5) M, release of somatostatin was inhibited at low concentrations and stimulated at high concentrations. However, both low and high concentrations of metenkephalin stimulated insulin secretion. A gradient of met-enkephalin from 0 to 10(-6) M caused only an inhibition of somatostatin release, whereas insulin release was stimulated. The effects of met-enkephalin on somatostatin release were antagonized by naloxone (10(-6) M). The metenkephalin-induced insulin secretion was partially, but not completely, blocked by naloxone. Naloxone (10(-6) M) alone changed the endocrine secretions by decreasing somatostatin release and by stimulating insulin release. Met-enkephalin may, therefore, be a physiologic regulator of pancreatic endocrine secretion.

Animals↗
PubMed1984

Autoradiographic localization of opioid receptors in the rat stomach.

The distribution of opioid receptors in the stomach has been studied using autoradiography of slide-mounted tissue sections incubated with [3H]D-Ala2,D-Leu5-enkephalin. The major sites of binding were the mucosa and the submucosal and deep muscular plexi. Other regions did not exhibit significant binding. These locations suggest that endogenous delta-opioid receptors may regulate mucosal ion transport and smooth muscle motility in the stomach.

Animals↗
PubMed1984

Gastrin release from isolated perfused rat stomach after vagotomy.

Postvagotomy hypergastrinemia persists in the isolated perfused rat stomach, but its cause is unknown. The possible role of cholinergic nervous pathways was investigated in the isolated vascularly perfused rat stomach after vagotomy. Atropine and hexamethonium, but not propranolol, inhibited postvagotomy hypergastrinemia. A nervous mechanism involving acetylcholine was further suggested by the inhibitory action of methionine-enkephalin on gastrin release after vagal section. Methacholine, a muscarinic receptor agonist, only weakly stimulated gastrin release from vagotomized stomachs when compared with shamoperated controls, indicating that a cholinergic drive was already in place. Immunocytochemical studies of antral tissue following vagotomy indicated that numbers of gastrin-containing cells (G-cells) were not increased after vagotomy but exhibited reduced intensity of gastrin staining when compared with control stomachs. It was concluded that basal hypergastrinemia may result from increased stimulation of a normal G-cell population by a cholinergic mechanism at the ganglionic level.

Animals↗
PubMed1983

Enkephalinergic control of somatostatin secretion from the perfused rat stomach.

A role for the enkephalins in the regulation of gastric somatostatin (SLI) secretion has been investigated in an isolated perfused rat stomach model. Both methionine- and leucine-enkephalins caused a dose-dependent inhibition of gastric inhibitory polypeptide (GIP) stimulated SLI secretion. Leu-enkephalin was one order of magnitude less potent than met-enkephalin: 50% inhibition by met-enkephalin was at 4 X 10(-9) M and with leu-enkephalin 3.5 X 10(-8) M. Naloxone (100 nM) had no effect on basal secretion but blocked the inhibitory action of met-enkephalin (1 nM or 1 microM). Vagal stimulation (7 V, 10 Hz, 5 ms) inhibited GIP-stimulated SLI release. Administration of naloxone partially reversed this inhibition, suggesting that endogenous opioids were at least partially responsible for vagally induced inhibition. A number of possible pathways by which endogenous enkephalins may modulate SLI release have been proposed.

Animals↗
PubMed1983

Adrenergic control of rat gastric somatostatin and gastrin release.

The effect of adrenergic agonists and antagonists on the secretion of gastric somatostatin-like immunoreactivity (SLI) and gastrin was investigated in an isolated, vascularly perfused rat stomach preparation. Two- to six-fold increases in SLI secretion induced by isoproterenol, epinephrine, and norepinephrine were completely abolished by propranolol but were not influenced by phentolamine. Propranolol did not alter glucagon- and DB-cAMP-induced stimulation of SLI release. Experiments in which the beta 2-agonist salbutamol and the beta 1- and beta 2-blockers practolol and H35/25 were used showed that both subtypes of beta receptors are involved. Gastrin secretion revealed only minor changes in dose-response studies with a wide range of isoproterenol concentrations (2 X 10(-8) to 1.5 X 10(-4) M). The results obtained in this study suggest that in rats 1) the SLI response to adrenergic agonism is predominantly mediated by beta receptors; 2) both beta 1- and beta 2-adrenergic receptors are involved; 3) under in vitro conditions, adrenergic agonism is a weak stimulus for gastrin secretion.

Adrenergic beta-Agonists↗
PubMed1982

Adrenergic and cholinergic interactions in rat gastric somatostatin and gastrin release.

The interactions of adrenergic and cholinergic influences on the gastric D cell were studied using an isolated perfused rat stomach in vitro. The sevenfold increase in the release of somatostatin-like immunoreactivity (SLI) in response to isoproterenol (4 . 10(-8) M) was dose-dependently inhibited by acetylcholine (10(-5) to 10(-8) M) whereas gastrin levels increased in a dose-dependent manner. Both inhibition of stimulated SLI and augmentation of gastrin release were completely abolished by atropine (10(-6) M). Isoproterenol (8 . 10(-9) M)-induced stimulation of SLI secretion was not altered by atropine. Antral exclusion completely eliminated gastrin secretion but basal and beta-adrenergic stimulated SLI release was not influenced. It is concluded that (1) cholinergic agonism reverses the stimulatory action of adrenergic agonists on the D cell, and (2) SLI from the rat stomach in vitro originates almost exclusively in the fundic region.

Acetylcholine↗
PubMed1981

Absence of a relationship between immunoreactive-gastrin and somatostatin-like immunoreactivity secretion in the perfused rat stomach.

The possible interaction between somatostatin-like immunoreactivity (SLI) and immunoreactive-gastrin release was studied in an isolated perfused rat stomach preparation. Gastrin release was abolished by antrectomy but basal and gastric inhibitory polypeptide-stimulated SLI levels were unchanged from control experiments, implicating the corpus as the major source of SLI released into the vasculature. Perfused stomachs of vagotomized rats exhibited basal hypergastrinaemia with no alteration in basal or stimulated SLI release, suggesting an uncoupling of SLI and gastrin release. This study indicated that SLI released into the vasculature originated in the acid secretory region of the stomach and therefore may be involved in the regulation of acid secretion at the level of the parietal cell mass.

Animals↗
PubMed1981

Actions of GIP.

Two structurally similar peptides were isolated from a preparation of GIP using an HPLC system. The major peptide corresponds to GIP1-42 and the minor has the sequence GIP3-42. GIP1-42 has both insulinotropic and somatostatinotropic activities, whereas GIP3-42 has only insignificant activity. GIP was also shown to potentiate insulin release initiated by D-glyceraldehyde, L-leucine/L-glutamine and 2-keto-isocaproic acid. No potentiation was observed with 2-ketocaproate. The 4 substrates studied are all metabolized but via different mechanisms.

Animals↗
PubMed1981

Gastric inhibitory polypeptide stimulated secretion of somatostatinlike immunoreactivity from the stomach: inhibition by acetylcholine or vagal stimulation.

The possible involvement of gastric somatostatinlike immunoreactivity (SLI) in the acid inhibitory action of gastric inhibitory polypeptide (GIP) was studied in an isolated perfused rat stomach. GIP, in a dose of 5 or 50 ng/mL, caused a 4- and 12-fold increase in SLI secretion, respectively. At the higher dose level the stimulated secretory rate declined throughout the perfusion suggesting that secretion exceeded the capacity to synthesize SLI under excessive GIP stimulation. Acetylcholine (10 microM) or vagal stimulation (7 V, 10 Hz, 5 ms) completely inhibited GIP-stimulated SLI secretion. It is therefore proposed that the acid inhibitory activity of GIP is probably mediated via release of gastric SLI and this action is under cholinergic control.

Acetylcholine↗
PubMed1980

Parathyroid hormone fragments in secretory granules of human parathyroid adenomata.

The composition of human parathyroid hormone immunoreactivity in the secretory granule fraction of parathyroid hormone adenomata was investigated. Granular extracts were separated by gel filtration and the eluates assayed by radioimmunoassay and sequence specific immunoradiometric assays detecting aminoterminal and carboxyterminal activity. About half of the extracted adenomata contained fragments besides intact hormone. The fragment composition varied from adenoma to adenoma.

Adenoma↗